Hoppa till innehållet
STOCKHOLM – June 19, 2023 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced its first named patient sales of its flagship drug Pepaxti in Greece. The sales were made possible through Oncopeptides’ partnership with Ariti S.A., a company specialized on medical and pharmaceutical supply in Greece.
Since receiving the approval of Pepaxti in the European Union and countries in the European Economic Area in August 2022, Oncopeptides have been focusing its launch efforts on Germany while also working to gain market access in other European countries.
“Although still at an early stage, I am happy that we now can supply in Greece and make a difference to patients there with a high unmet need,” says Monica Shaw, CEO of Oncopeptides. “As we work to launch across Europe we need to assess every country individually to find the optimal way to ensure we can start to sell and patients can get access to Pepaxti. We are happy to partner with Ariti S.A. in Greece, as they have a solid experience in multiple myeloma including close relationships with healthcare professionals in the market and good understanding of how to ensure timely access to the drugs within rare diseases such as Pepaxti.”
In her recent presentation at the company´s Annual General Meeting, Monica Shaw outlined commercial opportunities for Oncopeptides in Europe. You can find a video of the presentation on Oncopeptides website.
For more information including a Q&A for investors, please visit our website.